Oppenheimer analyst Steven Lichtman reiterated an Outperform rating and $105.00 price target on Tandem Diabetes Care (NASDAQ: TNDM) following comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE